Stock Taper
SCREENER COMPARE ANY 2 STOCKS
IVA
INVENTIVA S.A.
NASDAQ
$4.71
▼ DOWN 3.98% (-0.20)

KEY STATISTICS

Market Cap$244.58 M
52w High$7.98
52w Low$3.35
Dividend Yield—
Frequency—
P/E-1.59
Volume1.12M
Shares Out.51.98M

COMPANY

LEADERSHIP

Andrew Obenshain
CHIEF EXECUTIVE
Andrew Obenshain

ABOUT

SECTOR
Healthcare
WENT PUBLIC
July 10, 2020
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
73

PRICE TARGET

Target High$24.00
Target Low$12.00
Target Median$13.00
Target Consensus$15.33

UPCOMING EARNINGS

DateSep 25, 2026
DayFriday
Rev. Est.$4.76M
SEP
25
FRI

PRICE

$4.71 ▼ DOWN 3.98% (−$0.20)
$4.65$4.72$4.809:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM4.71

About Inventiva S.A.

https://www.inventivapharma.com ↗

Inventiva S.A. is a French clinical-stage biopharmaceutical company developing oral therapies for NASH, MPS, and other diseases, with lead candidates Lanifibranor and Odiparcil, and collaborations with AbbVie and Boehringer Ingelheim.

INDUSTRY

Biotechnology

A PRODUCT INVENTIVA S.A. IS KNOWN FOR

Lanifibranor
Lanifibranor

Lanifibranor, Inventiva's lead oral small molecule for MASH, is in Phase 3 trials, the only pan-PPAR agonist in development for this, with FDA Breakthrough Therapy and Fast Track designations.

COMPETITORS

COMPETITOR
MDGL COMPARE
VKTX COMPARE

Revenue by Geography

MapREGIONFY2022FY2023FY2024FY2025
JAPAN— $12.75M — —
CHINA$12.05M $4.61M ▼$9.13M ▲$4.48M ▼
FRANCE$125K $118K ▼$69K ▼—

ETFS HOLDING THIS STOCK

ETFS HOLDING
7
LISTED HERE
5
RANKED BY POSITION SIZE
SURI
1.70% · 313.5K
MEDI
0.38% · 34.0K
WELL.L
0.38% · 11.8K
APIE
0.00% · 10.1K
SPEU
0.01% · 7.9K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
66.57%
HOLDERS
70
TOP 12 OF 70 · RANKED BY POSITION SIZE
Samsara Biocapital, LLC
5.2M sh · $28.83M
Caligan Partners LP
5.0M sh · $27.61M
Paradigm Biocapital Advisors LP
4.0M sh · $22.2M
Millennium Management LLC
3.0M sh · $16.58M
Adar1 Capital Management, LLC
2.7M sh · $12.6M
Yiheng Capital Management, L.P.
2.6M sh · $15.31M
Ubs Group AG
2.6M sh · $12.29M
Franklin Resources Inc
2.5M sh · $11.63M
Polar Capital Holdings Plc
2.1M sh · $11.83M
Andera Partners
1.8M sh · $10.09M
Ally Bridge Group (Ny) LLC
1.5M sh · $6.97M
Yu Fan
1.5M sh · $8.32M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity5
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score2

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 3
3 GRADES IN THE LAST 12 MONTHS
Guggenheim BUY HC Wainwright & Co. BUY Canaccord Genuity BUY

SECTORS PEERS

PEERPRICE
AVTX$19.59COMPARE
ENTA$13.60COMPARE
OBIO$5.18COMPARE
IVVD$0.96COMPARE
RNAC$9.60COMPARE
EPRX$6.67COMPARE
CRBU$1.62COMPARE
TNYA$0.69COMPARE